Abivax released data on Tuesday. The stock jumped 34%. French biotech finally cracked the code on inflammatory bowel disease, or they didn't, or the data means nothing, or it means everything. Doesn't matter. The chart went up.
Here's what happened. Someone at Abivax ran a trial. They measured something in someone's bowels. The numbers looked good enough to type into a press release. Retail traders saw the press release. They bought the stock after it already moved 34%. This is called "doing research."
The experimental medicine treats bowel disease. Not cancer. Not Alzheimer's. Bowel disease. The company's entire market cap now hinges on whether this drug can successfully address intestinal inflammation better than existing treatments, which is a sentence that should make every growth investor question their life choices. But it won't.
You want to know what the data said? Doesn't matter. You wouldn't understand it anyway. Neither would I. Neither would the analysts who upgraded the stock this morning. We're all just watching lines move and pretending the press release about cytokine levels means something to us personally.
The technical setup was already there. Support at 12 euros. Resistance at 18. The stock was coiling. It was going to break out whether Abivax cured bowel disease or discovered a new way to make it worse. The catalyst is irrelevant. It's always irrelevant.
But sure, tell yourself you're investing in groundbreaking science. Tell yourself you read the clinical data. Tell yourself you understand the regulatory pathway for inflammatory bowel disease treatments in the European market. You don't. You saw a green candle and got excited.
The stock will give back 28% of this move within a week, and every single person who bought the top will swear they're long-term investors in French gastrointestinal innovation.
Photo by on Unsplash
Leave a Comment